Autolus Therapeutics plc
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
We found at least one documented issue that threatens the company itself — regardless of how the stock is currently valued.
Why this colour
Red instead of yellow since the update of 11/14/2026: equity ($27.4 million as of 9/30/2026) is smaller than the net loss of a single quarter ($55.1 million in the third quarter), and even before interest the business lost $146.9 million in the first nine months of 2026, with $23.0 million of interest expense on top, while a first-lien creditor requires minimum liquidity and minimum revenue. On the other side stand $248.4 million of liquid funds (runway including the second loan tranche into Q2 2028 on the company's own statement), growing revenue and a 57 percent gross margin; the quarterly report explicitly reports no going concern doubt. This is a judgement on the company, not on the share price or timing.
What the thesis turns on
Assessment: Opportunities & Risks
Autolus has taken the step from trial to market: its own cancer therapy approved, manufactured and sold — $113.1 million of product revenue in nine months of 2026 and a 57 percent gross margin in the third quarter. The balance sheet, however, shows who has first call on that revenue: $293.3 million of royalty liabilities owed to Blackstone and BioNTech at an imputed rate of about 15.80 percent, plus a first-lien secured facility from Perceptive since July 30, 2026. Of $1,585.6 million paid in, only $27.4 million of equity remained as of September 30, 2026, while cash stands at $248.4 million; including the undrawn second loan tranche, resources last into Q2 2028 on the company's own arithmetic. Not investment advice.
Market entry & revenue
AUCATZYL has been approved in the United States since November 8, 2024 and is selling: $113.1 million of product revenue in the first nine months of 2026, more than in all of 2025; $41.2 million in the third quarter, 95 percent more than a year earlier. The step from trial to market has demonstrably been taken.
Cost of sales & margin
In fiscal 2025 manufacturing cost $96.4 million against $75.4 million of revenue — on average, every treatment was subsidized. In the third quarter of 2026, $17.9 million of cost of sales stood against $41.2 million of revenue; the company reports a 57 percent gross margin after 55 percent in the second quarter. That is a central operating advance of the past twelve months.
Capital structure & ranking
As of 9/30/2026 the balance sheet carries $293.3 million of royalty and milestone liabilities (Blackstone $248.2 million, BioNTech $45.1 million) at an imputed rate of about 15.80 percent; in the first nine months of 2026, $35.3 million of imputed interest accrued while $8.1 million was paid. Since 7/30/2026 Perceptive has also held a first-priority security interest in substantially all assets, with minimum liquidity and minimum revenue covenants. Shareholders come last in this order.
Equity & loss history
Of $1,585.6 million of paid-in capital, $27.4 million of equity remained as of 9/30/2026; at the end of 2025 it was $178.1 million (−85 percent in nine months). That is less than the third-quarter net loss ($55.1 million). The accumulated deficit reached $1,552.6 million; by its own account the company has incurred recurring losses since it was founded in 2014.
Sales momentum & guidance
The guidance raised on 11/10/2026 — at least $150 million — requires at least $36.9 million in the fourth quarter after $113.1 million in nine months, less than the third quarter's $41.2 million, which itself was below the second ($45.7 million). That may be caution for a therapy billed per patient, but it does not assume an unbroken steep curve. The EU market including Germany remains on hold despite approval in July 2025.
Cash runway
As of 9/30/2026 there was $245.4 million of cash and $3.0 million of marketable securities, and $25 million from the second Perceptive tranche can be drawn until 1/30/2027. At an operating cash outflow of $108.9 million over nine months that equals roughly seven and a half quarters on paper, or roughly six to seven after the contractual minimum liquidity; the company itself states a runway "into Q2 2028" and explicitly reports no going concern doubt in its quarterly report.
Worth Noting
AUTL reached our research list through the event sweep of new SEC filings: the Form 8-K dated 8/3/2026 on a secured financing of up to $250 million and the quarterly report for the period ended 6/30/2026 filed eight days later. Updated on 11/14/2026 with the quarterly report for the period ended 9/30/2026 and the earnings release of 11/10/2026; no verifiable call transcript was available.
Risk of confusion over filer status: Autolus is a British company that reported on Form 20-F through fiscal 2022 (2023 quarterly updates initially on Form 6-K) and has voluntarily filed regular 10-Q reports since the third quarter of 2023 and 10-K and 8-K reports since fiscal 2023 — legally as a foreign private issuer. That status ends on 1/1/2027. The evidence in this analysis therefore comes from 10-K/10-Q and 8-K filings, not from 20-F/6-K.
Risk of confusion over the company name: market data sets still carry the former name "Autolus Therapeutics Ltd". According to the 2025 annual report, the company re-registered as a public limited company and was renamed "Autolus Therapeutics plc" on June 18, 2018 (CIK 0001730463).
Valuation figures as of fixed dates: market capitalization about $352 million at $1.32 per share (close on 11/10/2026); at first publication about $590.9 million at $2.22 (close on 8/13/2026). Both are point-in-time anchors, not forecasts.
Stock Watch
This analysis is as of November 14, 2026. Stock Watch will tell you what's changed at AUTL since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.20 $ to 2.50 $ · Last price: 1.20 $ (As of: November 13, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 11/14/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Autolus Therapeutics plc AUTL | 0.3 | – | 0.0 | -74.6 | -6,570.8 | 646.7 | -8.6 |
| Vertex Pharmaceuticals Inc VRTX | 136.2 | 32.1 | 27.5 | 54.8 | 38.1 | 9.6 | 24.0 |
| Regeneron Pharmaceuticals Inc REGN | 99.3 | 24.1 | 14.1 | 46.7 | 20.7 | 1.0 | 38.2 |
| Moderna Inc MRNA | 88.6 | – | 4.6 | -66.0 | -131.1 | -39.2 | 794.9 |
| argenx NV ARGX | 59.7 | 36.7 | 27.6 | 59.8 | 32.0 | 89.6 | 7.7 |
| BeiGene, Ltd. ONC | 47.1 | 74.4 | 29.5 | 89.4 | 19.1 | 40.2 | 10.2 |
| Royalty Pharma Plc RPRX | 38.2 | 37.5 | 24.0 | 99.8 | 100.3 | 5.1 | 78.4 |
| Revolution Medicines Inc RVMD | 35.8 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 167.6 |
| Genmab AS GMAB | 32.0 | 40.4 | 28.6 | 92.7 | 35.2 | -82.7 | 69.9 |
| Median of companies shown | 47.1 | 37.1 | 24.0 | 54.8 | 20.7 | 5.1 | 38.2 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 1 | -14 | -13 | -0.91 | -10 | 31 | 34 |
| 2017 | 2 | -23 | -20 | -1.43 | -16 | 143 | 149 |
| 2018 | 1 | -58 | -31 | -0.99 | -26 | 205 | 218 |
| 2019 | 3 | -248 | -124 | -2.88 | -101 | 255 | 304 |
| 2020 | 2 | -303 | -142 | -2.76 | -118 | 210 | 294 |
| 2021 | 2 | -140 | -142 | -1.97 | -118 | 313 | 406 |
| 2022 | 6 | -143 | -149 | -1.57 | -112 | 299 | 490 |
| 2023 | 2 | -180 | -208 | -1.20 | -146 | 111 | 375 |
| 2024 | 10 | -241 | -221 | -0.86 | -206 | 427 | 783 |
| 2025 | 76 | -281 | -288 | -1.08 | -284 | 178 | 589 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -0.22 | 15.40 | 0 | – | – | -51 | -52 |
| 2024: Q3 | -0.31 | -19.20 | 0 | -100.00 | – | -77 | -86 |
| 2024: Q4 | -0.09 | 80.00 | 0 | -98.40 | -95,193.10 | -38 | -62 |
| 2025: Q1 | -0.26 | -8.30 | 9 | -11.00 | -781.10 | -76 | -84 |
| 2025: Q2 | -0.18 | 18.20 | 21 | – | -229.00 | -73 | -80 |
| 2025: Q3 | -0.30 | 3.20 | 21 | – | -373.30 | -68 | -83 |
| 2025: Q4 | -0.34 | -277.80 | 24 | 83,534.20 | -371.90 | -67 | -91 |
| 2026: Q1 | -0.27 | -3.80 | 26 | 191.90 | -273.10 | -65 | -68 |
| 2026: Q2 | -0.15 | 16.70 | 46 | 118.40 | -85.60 | -25 | -26 |
| 2026: Q3 | -0.21 | 30.00 | 41 | 94.30 | -133.70 | -19 | -20 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Research
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.80 | -0.94 – -0.61 | 150 | 26.3% | 8 |
| 12/31/2027 | -0.63 | -0.94 – -0.31 | 192 | 20.5% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Autolus setzt künstliche Intelligenz nach eigener Darstellung bereits in Teilen von Forschung und Entwicklung ein — unter anderem bei der Identifikation möglicher Wirkstoffkandidaten — und will sie auf Wirkstoffsuche, Entwicklung, Vermarktung und Verwaltung ausweiten; verkauft wird jedoch ausschließlich die Zelltherapie AUCATZYL, ein eigener KI-Umsatz oder ein KI-Segment wird in Geschäfts- und Quartalsbericht nirgends ausgewiesen. Fortschreibung 11. November 2026: Der Quartalsbericht zum 30. September 2026 (10-Q vom 10. November 2026) und die Ergebnismitteilung (8-K, Anlage 99.1) nennen künstliche Intelligenz nicht; verkauft wird weiterhin ausschließlich AUCATZYL, ein KI-Umsatz oder KI-Segment wird nicht ausgewiesen. Die Einstufung „nutzt“ bleibt auf Basis des Geschäftsberichts 2025 bestehen.
View the full file — quotes, sources, reviewed filings
„We currently integrate artificial intelligence (“AI”) in certain of our research and development activities, including identification of potential product candidates, and are seeking to further integrate AI throughout our business."
Wir setzen künstliche Intelligenz („KI“) derzeit in bestimmten unserer Forschungs- und Entwicklungstätigkeiten ein, einschließlich der Identifikation möglicher Produktkandidaten, und streben an, KI in unserem gesamten Geschäft weiter zu verankern.
10-K · 2026-03-27 · View SEC filing
„We are exploring additional opportunities to incorporate AI into our processes for drug discovery, drug development, drug commercialization, and in connection with our general & administrative functions."
Wir prüfen weitere Möglichkeiten, KI in unsere Abläufe für Wirkstoffsuche, Arzneimittelentwicklung und Vermarktung sowie im Zusammenhang mit unseren allgemeinen Verwaltungsfunktionen einzubinden.
10-K · 2026-03-27 · View SEC filing
„We may also face increased competition from other companies that are using AI, some of whom may develop more effective methods than we and any of our business partners have, which could have a material adverse effect on our business, results of operations, or financial condition."
Wir könnten zudem verstärktem Wettbewerb durch andere Unternehmen ausgesetzt sein, die KI einsetzen und von denen einige wirksamere Methoden entwickeln könnten als wir und unsere Geschäftspartner, was sich wesentlich nachteilig auf unser Geschäft, unsere Ertragslage oder unsere Finanzlage auswirken könnte.
10-K · 2026-03-27 · View SEC filing
Filings Reviewed: 10-Q 2026-11-10 · 10-Q 2026-08-11 · 10-Q 2026-05-14 · 10-K 2026-03-27 · 10-Q 2025-11-12 · 10-Q 2025-08-12 · 10-K 2025-03-20
Rated on November 11, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 130.2%
- More than 10% revenue growth is expected for the coming year -52.5%
- Share count grows by less than 3% a year 41.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 235.5%
- Gross margin at 40% or higher and without meaningful erosion -27.8%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 82 m
- Return on capital at 15% or higher, or up versus two years ago -54.6%
- Insiders hold at least 10% or are net buyers 18.1%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 58.3%
- Exp. sales growth 3Y > 5% 59.6%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 59.6%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -182.0%
- ROCE > 15% -54.6%
- Expected return > 10% -95.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Piccina Cintia | U.S. CCO & Country Gen Manager | Sell | 6,713 | 2.34 | 15,682 |
| Sep 1, 2026 | Piccina Cintia | U.S. CCO & Country Gen Manager | Other | 20,000 | 2.35 | 47,000 |
The company
About the Company
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
- Employees
- 752
- Headquarters
- London, United Kingdom
- Address
- The Mediaworks, W12 7FP London, United Kingdom
- Phone
- 44 20 3829 6230
- Website
- autolus.com
- IPO Date
- 06/22/2018
- ISIN
- US05280R1005
Management
| Name | Title | Birth Year |
|---|---|---|
| Christian Martin Itin Ph.D. | CEO & Director | 1964 |
| Martin Pule M.D., MBBS | Founder, Senior VP & Chief Scientific Officer | 1972 |
| Robert F. Dolski | Senior VP & CFO | 1971 |
| Christopher Vann | Senior VP & COO | 1965 |
| Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer | 1980 |
| Miranda Neville | Senior VP & Chief Technology Officer | 1975 |
| Alex Driggs | Senior VP of Legal Affairs & General Counsel and Secretary | 1976 |
| Alexander Swan | Senior VP & Chief Human Resources Officer | 1965 |
| Christopher Williams Ph.D. | Senior VP & Chief Business Development Officer | 1980 |
| Matthias Will M.D. | Senior VP & Chief Development Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 11/10/2026 Autolus Therapeutics plc (AUTL): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.